

## MARKET WRAP UP

- Key benchmark indices ended with small gains in a quiet session of trade. The S&P BSE Sensex rose 28.05 points or 0.09% to settle at 31,596.06. The Nifty 50 rose 4.55 points or 0.05% to settle at 9,857.05.
- The S&P BSE Mid-Cap index rose 0.8%. The S&P BSE Small-Cap index advanced 0.37%.

## DERIVATIVES WATCH

- Nifty August series futures witnessed a fresh long position build up. Open Interest has been increased by 1337 contracts at the end of the day.
- Long position build up for the August series has been witnessed in ICICIBANK, CESC, BERGEPAIN.
- Short position build up for the August series has been witnessed in RELIANCE, BHARTIARTL, HDFCBANK.
- Unwinding of position for the August series has been witnessed in SBIN, HDFC, INFY.

## CORPORATE NEWS

- Infosys crisis**-The entire board of the company offered to resign on Thursday. The majority of the board of the firm, except Punita Sinha and Roopa Kudwa are likely to resign, paving way for Nandan Nilekani to step in as a crisis manager for the firm.
- Indian Hume Pipe Company** has secured work order book worth Rs100.46 crore from Municipal Corporation Bilaspur, Chattisgarh for augmentation of water supply scheme part-II- distribution system, Bilaspur, Chattisgarh under AMRUT mission.
- MEP Infrastructure Developers** announced that National Highways Authority of India (NHAI) engaged it as user fee collection agency for Chennasamudram fee plaza in TamilNadu.
- Lupin** has received approval from the USFDA for Quetiapine Fumarate Extended-Release Tablets. The tablets are the AB rated generic equivalent of AstraZeneca Pharmaceuticals LP's Seroquel XR tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg. Lupin, through its USA subsidiary Lupin Pharmaceuticals, Inc has initiated voluntary recall of tablets Mibelas 24 Fe from the USA market as they are "out of sequence." According to a notification issued by the US Food and Drug Administration (USFDA), as many as 24,652 tablets are being recalled under 'class-I' classification.
- Zydus Cadila** has received final approval from the USFDA to market candesartan cilexetil tablets used for treatment of hypertension in the strengths of 4 mg, 8 mg, 16 mg and 32 mg.
- Glenmark Pharmaceuticals** said that Glenmark Pharmaceuticals Inc., USA has been granted final approval by the USFDA for Triamcinolone Acetonide Ointment USP, 0.1%, the generic version of Kenalog Ointment, 0.1%, of Mylan Pharmaceuticals Inc.
- Alembic Pharmaceuticals** has sold its formulations manufacturing facility at Baddi to Scott Edil Pharmacia (SEPL).
- IndusInd Bank** has emerged as frontrunner for deal with non-banking finance company Bharat Financial Inclusion.
- Dilip Buildcon** has signed a term sheet with Chhatwal Group Trust (Shrem Group) today for divestment by way of sale, transfer or disposal of 24 subsidiaries of the company.
- Bank of India** has reduced interest rate on savings bank accounts by 50 basis points to 3.5% on deposits of up to Rs 50 lakh. However, the bank will continue to pay 4% interest on deposits of above Rs 50 lakh.
- Mcleod Russel India** has decided to dispose of its Bhatpara Tea Estate, a loss-making unit of the company in Dooars, subjected to necessary approvals.

## INDEX CHART



## GLOBAL NEWS

- U.S. new home sales plunged by 9.4% to an annual rate of 571,000 in July from the revised June rate of 630,000.
- U.K. gross domestic product increased 0.3% sequentially in the second quarter, slightly faster than the 0.2% expansion posted in the first quarter. Year-on-year, GDP growth came in at 1.7%, in line with preliminary estimate.
- Eurozone consumer confidence rose by 0.2 points to -1.5 in August, unchanged from the previous month at -2.3.
- Germany's composite output index climbed to a 2-month high of 55.7 in August from 54.7 in July. The flash services PMI rose to 53.4 from 53.1 in July. Similarly, the factory PMI increased to 59.4 in August from 58.1 in July.

## ECONOMIC NEWS

- Crude Oil traded at US\$ 48.16/bbl (IST 17:00).
- INR strengthened to Rs. 64.03 from Rs. 64.11 against each US\$ resulting in daily change of 0.12%.
- The new Rs 200 currency note will be introduced in the market on 25th August, 2017. Along with the new Rs 200 note, the government has also confirmed a new Rs 50 note.
- India and Nepal inked eight pacts, including on cooperation in countering drug trafficking.
- The Directorate General of Civil Aviation (DGCA) is to come out with a draft rules for operations of drone in India, which may mandate a remote pilot licence to operate drones beyond a certain weight in the country.
- State oil companies have raised prices of petrol and diesel by a steep Rs 5.64 per litre and Rs 3.72 per litre respectively since July 1 through daily revisions that have largely gone unnoticed.
- India's plan to bring in marketing rules to curb unethical promotional practices in the country's drug industry faces an indefinite delay after it hit a legal roadblock, marking a setback for public health groups. The country's law ministry has rejected draft marketing rules, which were prepared by the Department of Pharmaceuticals (DoP) after nearly two years of deliberations, saying they cannot be passed under the proposed legal framework.

For Private Circulation Only

## FORTHCOMING EVENT

### BOARD MEETINGS AS ON 25/08/2017

- Atlas Cycles (Haryana) Limited Results
- Kiri Industries Limited Results
- SPML Infra Limited Results
- Venus Remedies Limited Results/Others

### BOARD MEETINGS AS ON 26/08/2017

- Arshiya Limited Results
- Elgi Rubber Company Limited Results
- La Opala RG Limited Results
- Lux Industries Limited Results
- Remsons Industries Limited Results
- Tejas Networks Limited Meeting Updates
- TIL Limited Results

### BOARD MEETINGS AS ON 28/08/2017

- 8K Miles Software Services Limited Results/Others
- AMD Industries Limited Results/Others
- Aurionpro Solutions Limited Results
- Camlin Fine Sciences Limited Results
- IL&FS Eng & Construction Co. Ltd Results
- Mold-Tek Packaging Limited Results/Others
- Mold-Tek Technologies Limited Results/Others
- Prakash Steelage Limited Results
- Rajshree Sugars & Chemicals Limited Results/Others
- Suryalakshmi Cotton Mills Limited Results

### CORPORATE ACTIONS AS ON 28/08/2017

- Ambika Cotton Mills Limited Interim Dividend Rs 10/- Per Share
- Skipper Limited Dividend - Rs 1.55 Per Share
- Pincon Spirit Limited Dividend - Re 0.75 Per Share

## Indian Markets

Indices	Close	Previous	Change (%)
NIFTY 50	9857.05	9852.50	0.05%
S&P BSE SENSEX	31596.06	31568.01	0.09%
NIFTY MID100 FREE	17963.95	17856.65	0.60%
NIFTY SML100 FREE	7515.50	7468.15	0.63%

## Exchange Turnover

Market	Current	Previous
NSE Cash	24542.74	23817.05
NSE F&O	1013214.64	715860.83

## Previous FII Positions ( IN CRORE )

ACTIVITIES	Cash	F&O
NET BUY	-	94.16
NET SELL	1157.52	-

## Sectoral Indices

Indices	Close	Previous	Change (%)
BSE BANKEX	27454.20	27455.08	0.00%
BSE IT	10021.64	9953.22	0.69%
BSE CG	17161.36	17071.36	0.53%
BSE OIL & GAS	14861.52	14879.45	-0.12%
BSE FMCG	10018.53	10042.20	-0.24%
BSE AUTO	23548.00	23513.38	0.15%
BSE HC	13226.29	12899.31	2.53%
BSE POWER	2244.21	2238.53	0.25%
BSE METAL	13054.54	12994.72	0.46%

## Top Gainers

SCRIP NAME	Close	Previous	Change (%)
AUOPHARMA	732.15	698.65	4.79%
LUPIN	992.50	955.85	3.83%
SUNPHARMA	483.00	469.20	2.94%
DRREDDY	2088.15	2030.95	2.82%
CIPLA	574.05	559.15	2.66%

## Asia Pacific Markets

Indices	Close	Previous	Change (%)
Nikkei225	19353.77	19435.64	-0.42%
HangSeng	27518.60	27401.67	0.43%
Straits Times	3272.16	3260.05	0.37%
Shanghai	3271.51	3287.70	-0.49%
Kospi	2375.84	2366.40	0.40%
Jakarta	5894.12	5914.02	-0.34%
Taiwan	10488.96	10406.81	0.79%
KLSE Composite	1775.50	1772.94	0.14%
All Ordinaries	5801.70	5792.70	0.16%

## Top Losers

SCRIP NAME	Close	Previous	Change (%)
HCLTECH	867.50	880.00	-1.42%
ADANI PORTS	380.05	385.00	-1.29%
ACC	1781.50	1801.90	-1.13%
BAJAJ-AUTO	2728.55	2754.65	-0.95%
BOSCHLTD	21676.25	21882.40	-0.94%

## DISCLAIMER

This document has been prepared by Shriram Insight Share Brokers Ltd. and is meant for sole use by the recipient and not for circulation. This document is not to be reported or copied or made available to others. The information contained herein is from sources believed reliable. It should not be considered to be taken as an offer to sell or a solicitation to buy any security or as an official confirmation of any transaction. We do not represent that it is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The investments discussed or recommended in this report may not be suitable for all investors. Shriram Insight Share Brokers Ltd stock Recommendation Service is a general recommendation service and is not to be construed as an individual investor specific Portfolio Management and Advisory Service.

The user assumes the entire risk of any use made of this information. Each recipient of this document should arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult its own advisors to determine the merits and risks of such an investment.

Shriram Insight Share Brokers Ltd shall not be responsible for any loss or liability incurred to the user as a consequence of his or any other person on his behalf taking any investment decisions based on the information, recommendations, research reports, analysis, quotes, etc. provided on the web site.

Shriram Insight Share Brokers Ltd and its affiliated company (ies), their directors and employees may:

(a) from time to time, having a long or short position in, and buy or sell the securities of the company (ies) recommended.

(b) be engaged in any other transaction involving such securities and act as a market maker in the securities of the company (ies) or lender / borrower to such company (ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Shriram Insight Share Brokers Ltd shall also not be liable for errors, omissions or typographical errors, disruption delay, interruption, failure, deletion or defect of/in the Service provided by it.

All Users of the Service in countries other than India understand that by using the Service, they may be violating the local laws in such countries. If the User chooses

EQUITIES DERIVATIVES COMMODITIES\* DP SERVICES MUTUAL FUNDS RESEARCH